Mantle cell lymphoma · 4 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bortezomib and Rituximab (VR) Variant #01 | — | R 58 571 | 60d | ~12.8 mo | — | ~5 | ~R 241 048 PFS proxy · indirect | 1 |
Lenalidomide monotherapy Variant #01 | — | R 2 178 | 28d | — | — | 24 | R 52 272 PFS proxy | 1 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | — | — | 1 | — | 2 |
Observation Partial | — | — | — | — | — | — | — | 1 |
4 of 4 regimens shown